• Multiomics Reveals Mechanisms of Bifendate and Muaddil Sapra

  2026-07-17

  This study leverages multiomics profiling to systematically dissect the therapeutic mechanisms of bifendate and muaddil sapra in acute liver injury. By integrating transcriptomic and proteomic analyses, the research identifies key gene modules, regulatory pathways, and molecular targets underpinning drug efficacy, providing a comprehensive framework for future therapeutic strategies.

• Panobinostat (LBH589): Reliable Workflows for Cancer Cell As

  2026-07-16

  This article provides an in-depth, scenario-driven guide for optimizing cell viability, proliferation, and apoptosis assays using Panobinostat (LBH589) (SKU A8178). Grounded in recent research and practical laboratory experience, it addresses common workflow challenges and demonstrates how this broad-spectrum HDAC inhibitor delivers reproducible, interpretable results for cancer and epigenetic regulation studies.

• Improving In Vitro Drug Response Evaluation in Cancer Resear

  2026-07-16

  Schwartz's dissertation rigorously distinguishes between proliferative arrest and cell death in in vitro drug response assays, highlighting the need for more precise evaluation metrics in cancer pharmacology. The findings provide a clearer framework for interpreting anti-proliferative and cytotoxic drug effects, informing both assay design and translational utility.

• Tacalcitol Monohydrate in Precision NGF and Cancer Co-Therap

  2026-07-15

  Explore the advanced mechanisms of Tacalcitol monohydrate, a synthetic analog of vitamin D3, in orchestrating nerve growth factor induction and enhancing anticancer efficacy. This article uniquely reveals how molecular insights and protocol precision drive next-generation applications in dermatology and oncology.

• Tacalcitol Monohydrate Sensitizes Colorectal Cancer to 5-FU

  2026-07-15

  This study demonstrates that tacalcitol monohydrate, a synthetic analog of vitamin D3, enhances the anticancer efficacy of 5-fluorouracil (5-FU) in colorectal cancer cells by downregulating thymidylate synthase through VDR-mediated mechanisms. These findings provide a mechanistic basis for combination therapies targeting resistant colorectal tumors.

• Bazedoxifene as an Antimalarial: SERM Repurposing and Mechan

  2026-07-14

  The reference study reveals that bazedoxifene, a third-generation selective estrogen receptor modulator (SERM), exhibits potent antimalarial activity by inhibiting hemozoin formation in Plasmodium falciparum. These findings underscore the therapeutic potential of SERM repurposing for malaria, especially given the slow pace of new antimalarial development and rising drug resistance.

• Nonivamide (Capsaicin Analog): Protocols for Cancer and TRPV

  2026-07-14

  Nonivamide, a potent capsaicin analog, delivers unique advantages for TRPV1-driven oncology and neuroimmune assays. This guide translates the latest mechanistic findings into practical protocols, troubleshooting strategies, and advanced workflows for cancer and chronic itch models.

• Ferrostatin-1 (Fer-1): Potent Inhibitor of Ferroptosis in Re

  2026-07-13

  Ferrostatin-1 (Fer-1) is an established, selective inhibitor of ferroptosis, showing nanomolar efficacy in preventing iron-dependent lipid peroxidation in cellular models. It is a crucial tool in cancer biology and neurodegenerative disease research, offering mechanistic clarity for ferroptosis assays. This article details its biological rationale, mechanism, and experimental benchmarks with citation-rich evidence.

• Context-Dependent Senescence and Bcl-xL Sensitivity in Prost

  2026-07-13

  This study distinguishes between DNA damage-induced and enzalutamide-induced senescence in prostate cancer, revealing that only the former confers sensitivity to Bcl-xL inhibitors. These findings refine the understanding of how senescence phenotypes dictate therapeutic vulnerabilities, with implications for targeted interventions in castration-resistant prostate cancer research.

• BIRB 796 (Doramapimod): Precision Tool for Inflammation Rese

  2026-07-12

  BIRB 796 (Doramapimod) uniquely combines potent, selective p38α MAPK inhibition with a dual-action mechanism that accelerates dephosphorylation, enabling highly reproducible inflammation and apoptosis assays. Discover workflow enhancements, troubleshooting strategies, and insights from the latest structural biology to maximize its impact across disease models.

• SP2509: Lysine-Specific Demethylase 1 Antagonist in AML Rese

  2026-07-10

  SP2509 is a potent, selective LSD1 antagonist enabling robust apoptosis induction and differentiation in acute myeloid leukemia (AML) models. This guide covers practical workflows, troubleshooting insights, and actionable tips to maximize the impact of SP2509 in cancer epigenetics research.

• RNA Pol II Inhibition Triggers Apoptosis Beyond Transcriptio

  2026-07-09

  Harper et al. (2025) reveal that cell death from RNA Pol II inhibition is not a passive consequence of lost transcription but an actively signaled apoptotic response, specifically triggered by the depletion of hypophosphorylated RNA Pol IIA. This insight uncovers a novel surveillance pathway linking nuclear transcription machinery to mitochondrial apoptosis, challenging prevailing assumptions in DNA damage response and cancer biology research.

• Phosphatase Inhibitor Cocktail 3: Optimizing Serine/Threonin

  2026-07-09

  Harness the power of Phosphatase Inhibitor Cocktail 3 (100X in DMSO) to preserve critical phosphorylation events in your serine/threonine signaling research. This guide distills experimental best practices, advanced workflow enhancements, and troubleshooting tactics for robust phosphoprotein analysis—enabling publication-ready results even in demanding applications like FAK pathway studies.

• Wnt-C59: Precision PORCN Inhibitor Workflows in Cancer Biolo

  2026-07-08

  Wnt-C59’s nanomolar potency and pathway selectivity enable robust, reproducible inhibition of Wnt/β-catenin signaling, making it an essential tool for dissecting Wnt-driven oncogenesis and stem cell dynamics. This guide delivers actionable workflow strategies, troubleshooting insights, and a practical translation of recent mechanistic breakthroughs for optimized research outcomes.

• Topotecan for Recurrent Small Cell Lung Cancer: Clinical Evi

  2026-07-08

  This article reviews the clinical and translational impact of Topotecan in treating recurrent small cell lung cancer (SCLC), focusing on innovations in dosing regimens, efficacy, and safety. The discussed reference consolidates phase II/III trial outcomes, highlighting Topotecan's role as a tolerable and effective option for relapsed SCLC.

450 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page